{"id":50454,"date":"2025-12-11T22:26:29","date_gmt":"2025-12-11T14:26:29","guid":{"rendered":"https:\/\/flcube.com\/?p=50454"},"modified":"2025-12-11T22:26:32","modified_gmt":"2025-12-11T14:26:32","slug":"juncell-therapeutics-files-for-hkex-ipo-pioneering-chemo-free-til-therapy-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50454","title":{"rendered":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors"},"content":{"rendered":"\n<p><strong>Shanghai Juncell Therapeutics Co., Ltd.<\/strong> (&#8220;JunCell Biologics&#8221;) released its prospectus, announcing its intention to list on the <strong>Hong Kong Stock Exchange<\/strong>. The company is a cell\u2011therapy developer focused on solid tumors, featuring <strong>GC101<\/strong>, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-and-financial-overview\">IPO and Financial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Prospectus Date<\/strong><\/td><td>11\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>R&amp;D Expenditure 2023<\/strong><\/td><td>RMB 57.6\u202fmillion<\/td><\/tr><tr><td><strong>R&amp;D Expenditure 2024<\/strong><\/td><td>RMB 91.0\u202fmillion<\/td><\/tr><tr><td><strong>R&amp;D Expenditure H1\u202f2025<\/strong><\/td><td>RMB 52.8\u202fmillion<\/td><\/tr><tr><td><strong>R&amp;D CAGR (2023\u20112024)<\/strong><\/td><td>58% year\u2011over\u2011year growth<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Advance GC101 clinical trials; expand DeepTIL\/NovaGMP platforms; pipeline expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>DeepTIL\u2122<\/strong><\/td><td>Dual\u2011Free Platform for TIL cell enrichment and expansion; enables chemo\u2011free manufacturing<\/td><\/tr><tr><td><strong>NovaGMP\u2122<\/strong><\/td><td>Non\u2011viral vector gene modification technology; supports engineered TIL and off\u2011the\u2011shelf products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline\">Core Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>GC101<\/strong><\/td><td>Solid tumors (TIL therapy)<\/td><td>Clinical development<\/td><td><strong>World\u2019s first TIL therapy without lymphodepletion or IL\u20112<\/strong>; Q2\u202f2026 China IND filing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion:<\/strong> HKEX listing provides estimated <strong>USD 40\u201160\u202fmillion<\/strong> raise to fund Phase\u202f1\/2 trials for GC101 across <strong>melanoma, lung, and cervical cancers<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> DeepTIL platform removes the need for high\u2011dose chemo conditioning, addressing a <strong>major safety and accessibility barrier<\/strong> for TIL adoption.<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Global TIL therapy market projected at <strong>$2.5\u202fbillion<\/strong> by 2030; China\u2019s solid\u2011tumor cell\u2011therapy market growing at <strong>35% CAGR<\/strong>, driven by unmet need in checkpoint\u2011refractory patients.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding Juncell\u2019s listing timeline, R&amp;D spend projections, and GC101 clinical milestones. Actual results may differ due to market conditions, regulatory feedback, or competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/sehk25121000411_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk25121000411_c.\"><\/object><a id=\"wp-block-file--media-13fde5c2-8d07-464b-8dda-a8702cd56778\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/sehk25121000411_c.pdf\">sehk25121000411_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/sehk25121000411_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-13fde5c2-8d07-464b-8dda-a8702cd56778\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Juncell Therapeutics Co., Ltd. (&#8220;JunCell Biologics&#8221;) released its prospectus, announcing its intention to list&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50456,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,2643],"class_list":["post-50454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-juncell-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Juncell Therapeutics Co., Ltd. (&quot;JunCell Biologics&quot;) released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50454\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Shanghai Juncell Therapeutics Co., Ltd. (&quot;JunCell Biologics&quot;) released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50454\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T14:26:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T14:26:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors\",\"datePublished\":\"2025-12-11T14:26:29+00:00\",\"dateModified\":\"2025-12-11T14:26:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1104.webp\",\"keywords\":[\"IPO\",\"Juncell Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50454#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50454\",\"name\":\"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1104.webp\",\"datePublished\":\"2025-12-11T14:26:29+00:00\",\"dateModified\":\"2025-12-11T14:26:32+00:00\",\"description\":\"Shanghai Juncell Therapeutics Co., Ltd. (\\\"JunCell Biologics\\\") released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50454\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50454#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Juncell Therapeutics Co., Ltd. (\"JunCell Biologics\") released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50454","og_locale":"en_US","og_type":"article","og_title":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors","og_description":"Shanghai Juncell Therapeutics Co., Ltd. (\"JunCell Biologics\") released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.","og_url":"https:\/\/flcube.com\/?p=50454","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-11T14:26:29+00:00","article_modified_time":"2025-12-11T14:26:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50454#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50454"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors","datePublished":"2025-12-11T14:26:29+00:00","dateModified":"2025-12-11T14:26:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50454"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50454#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","keywords":["IPO","Juncell Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50454#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50454","url":"https:\/\/flcube.com\/?p=50454","name":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50454#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50454#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","datePublished":"2025-12-11T14:26:29+00:00","dateModified":"2025-12-11T14:26:32+00:00","description":"Shanghai Juncell Therapeutics Co., Ltd. (\"JunCell Biologics\") released its prospectus, announcing its intention to list on the Hong Kong Stock Exchange. The company is a cell\u2011therapy developer focused on solid tumors, featuring GC101, the world\u2019s first tumor\u2011infiltrating lymphocyte (TIL) therapy that eliminates high\u2011intensity lymphodepleting chemotherapy and IL\u20112 administration.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50454#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50454"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50454#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","width":1080,"height":608,"caption":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50454#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo\u2011Free TIL Therapy for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50454"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50454\/revisions"}],"predecessor-version":[{"id":50457,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50454\/revisions\/50457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50456"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}